Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

EXpanded CELL ENdocardiac Transplantation (EXCELLENT) (EXCELLENT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02669810
Recruitment Status : Recruiting
First Posted : February 1, 2016
Last Update Posted : July 8, 2019
Sponsor:
Information provided by (Responsible Party):
CellProthera

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The main purpose of this phase I/IIB is to evaluate the safety, the tolerance and the first efficacy trends of intracardiac injection of ProtheraCytes (autologous PB-CD34+ Stem Cells after automated ex-vivo expansion with the StemXpand machine) in patients with a De Novo acute myocardial infarction and decreased ejection fraction. ProtheraCytes will be reinjected using a dedicated catheter pushed through the femoral artery up to the left ventricle, thus avoiding open chest surgery.

Condition or disease Intervention/treatment Phase
Acute Myocardial Infarction Drug: PROTHERACYTES Device: Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation) Phase 2

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicentric Controlled Phase I / IIb Study Evaluating the Safety and the Efficacy of in Vitro Expanded Peripheral Blood CD34+ Stem Cells Output by the StemXpand® Automated Process, and Injected in Patients With an Acute Myocardial Infarction and a Left Ventricle Ejection Fraction (LVEF) Remaining Below or Equal to 45% After PTCA and Stent(s) Implantation Versus Standard of Care.
Actual Study Start Date : September 25, 2015
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: PROTHERACYTES
The interventional investigators will perform the ProtheraCytes® endocardiac injections using the HELIX® catheter introduced via the femoral route up to the left ventricle cavity.
 Drug: PROTHERACYTES
ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
Active Comparator: Standard of Care
Patients will undergo standard of care procedure (PTCA Percutaneous Transluminal Coronary Angioplasty and stent(s) implantations)
 Device: Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Proportion of adverse events (including MACE), defined as the proportion of subjects with at least one adverse event from baseline until 6 months. [ Time Frame: 6 Months ]

Secondary Outcome Measures :
  1. Improvement of the Left Ventricle End Systolic Volume index will be assessed by cMRI. The left ventricular volumes will be indexed to body surface area. [ Time Frame: 6 months ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • De Novo Anterior wall AMI with or without ST segment elevation and with a detection of rise and/or fall of cardiac biomarker values (troponin) with at least one value above the 99th percentile of the upper reference limit.
  • LVEF ≤ 45% after stent(s) implantation: Combination of a LVEF ≤ 45 % and of anterior akinetic segment(s) - by echography at Day 2 after stent(s) mplantations
  • Age must be ≥ 18 and ≤ 75 years
  • Men and Non-pregnant non-lactating women who take efficacious contraceptive measures such as oral contraceptive medications or efficacious and permanent intra-uterine device (drug eluted or not) (IUD) or subcutaneous permanent contraceptive implants or menopaused women (at least a 2 years confirmed menopause) or surgically sterilized women.
  • Having previously signed a written informed consent prior to any study- specific procedures.
  • LVEF remaining ≤ 45% assessed by cMRI at Day 7 +/- 2 days after stent(s) implantation.
  • Identification of anterior akinetic segment(s) of interest assessed by cMRI at Day 7 +/- 2 days after stent(s) implantation.
  • Identification of non-viability of anterior segment(s) of interest assessed by perfusion 99mTc SPECT uptake at a day between Day 7 +/- 2 days and Day 10 +/- 2 days after stent(s) implantation.

Exclusion Criteria:

  • Absence of stent(s) implantation
  • Previous and known symptomatic CHF, from class II to IV (included)
  • History of CABG surgery
  • History of former significant mitral valve replacement surgery or heart transplantation.
  • Severe valve disease: mitral, aortic stenosis / insufficiency.
  • Diagnosis of non-ischemic dilated cardiomyopathy due to valvular dysfunction, mitral regurgitation, tachycardia, or myocarditis
  • Aortic stenosis as determined as valve area less than 1 cm2 that prohibits.catheter access to LV
  • Presence of a prosthetic / mechanical aortic or mitral valve or heart constrictive device.
  • Documented presence of a known LV thrombus
  • Sepsis
  • Endocarditis
  • Infectious pericarditis
  • Pericardial tamponade
  • Left ventricular aneurysm, collagen tissue disease
  • Severe peripheral vascular disease precluding femoral artery access as determined at the time of original catheterization.
  • Pacemaker, implantable cardiac defibrillator, and intra-cerebral aneurysm clips.
  • History of metallic foreign body in their eye
  • Severe claustrophobia
  • Former or current aortic dissection
  • Inadequate bone marrow function: Haemoglobin < 10 g/dL and Platelet count < 100 x 109 / L
  • Previous G-CSF or other Hematopoietic Growth Factor administrations.
  • Blood transfusion(s) within the previous 4 weeks (to exclude the potential of non-autologous ACPs (Angiogenic Cells Precursors) in the harvested blood).
  • Hepatic failure or history of liver cirrhosis or hepatic severe impairment.
  • Constitutional or acquired coagulopathy
  • Treated chronic renal failure, or haemodialysis or renal severe impairment (creatinine clearance < 30ml/min).
  • Prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer or previous cancer in complete response without any treatment in the last 5 years.
  • History of prior mediastinal radiation exposure
  • Serious underlying medical conditions at the investigator's discretion, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, active autoimmune disease, Amyotrophic Lateral Sclerosis, Systemic Lupus, Multiple Sclerosis).
  • Chronic immunomudulatory or cytotoxic drug treatment intake.
  • Active bleeding or major surgery within 1 month.
  • Human immunodeficiency HIV1-2, HTLV1, HTLV2 (according to 2006/17/EC)
  • Hepatitis B (without prior vaccination) and C (according to 2006/17/EC)
  • Syphilis (according to 2006/17/EC)
  • Chronic Obstructive Pulmonary Disease.
  • Active participation in any other clinical trials
  • Current or recent treatment (within the 60 days period before PTCA and stent(s) implantation) with another investigational drug or procedure).
  • Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.
  • Requirement of i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump) between Day 7 +/- 2 days and Day 10 +/- 2 days after stent(s) implantation.
  • Splenomegaly
  • Phenylacetonuria
  • History of iron-Dextran allergy
  • History of murin protein allergy
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02669810


Contacts
Layout table for location contacts
Contact: Frederic Flandrin 0033642743533 fflandrin@cellprothera.com

Locations
Layout table for location information
France
CHU de Grenoble Recruiting
Grenoble, France
Contact: Gérald Vanzetto, MD, PhD         
Institut Jacques Cartier Not yet recruiting
Massy, France
Contact: Thierry Lefèvre, MD         
CHU Montpellier Arnaud-De-Villeneuve Recruiting
Montpellier, France
Contact: François Roubille, MD         
Hôpital Haut Levèque Recruiting
Pessac, France
Contact: Lionel Leroux, MD         
Hôpital de Rangueil Recruiting
Toulouse, France
Contact: Jérôme Roncalli, MD,PhD         
Principal Investigator: Jérôme Roncalli, MD, PhD         
United Kingdom
University of Edinburgh Recruiting
Edinburgh, United Kingdom
Contact: David New, MD PhD         
Leeds University & Leeds Teaching Hospitals NHS Trust Recruiting
Leeds, United Kingdom
Contact: John Greenwood, MD PhD         
Sponsors and Collaborators
CellProthera
Investigators
Layout table for investigator information
Study Director: Frederic Flandrin CellProthera
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: CellProthera
ClinicalTrials.gov Identifier: NCT02669810    
Other Study ID Numbers: EudraCT 2014-001476-63
First Posted: February 1, 2016    Key Record Dates
Last Update Posted: July 8, 2019
Last Verified: July 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Infarction
Ischemia
Pathologic Processes
Necrosis
 Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases